The failure of a crucial pivotal study consigns Blueprint’s lead drug, Ayvakit, to a tiny niche.
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
Positive data should pave the way for ripretinib’s approval in fourth-line GIST, but investors are already eyeing a bigger opportunity.
The small-molecule oncology player zeroes in on its first commercial opportunity.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.